BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37042127)

  • 1. Unraveling the significance of TSHR mutations in indeterminate thyroid cytology specimens.
    Andrianus S; Gubbiotti MA; Mandel SJ; Nikiforov YE; Baloch Z
    Diagn Cytopathol; 2023 Jul; 51(7):406-413. PubMed ID: 37042127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
    Desai D; Lepe M; Baloch ZW; Mandel SJ
    Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
    Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
    Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
    Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
    Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.
    Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; Hodak SP; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
    Cancer; 2014 Dec; 120(23):3627-34. PubMed ID: 25209362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
    Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
    Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
    Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
    Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer.
    Chia SY; Milas M; Reddy SK; Siperstein A; Skugor M; Brainard J; Gupta MK
    J Clin Endocrinol Metab; 2007 Feb; 92(2):468-75. PubMed ID: 17118994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory.
    Rosario PW
    Thyroid; 2014 Jul; 24(7):1115-20. PubMed ID: 24684285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
    Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
    Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risk and clinicopathological characteristics of thyroid nodules harboring thyroid-stimulating hormone receptor gene mutations.
    Mon SY; Riedlinger G; Abbott CE; Seethala R; Ohori NP; Nikiforova MN; Nikiforov YE; Hodak SP
    Diagn Cytopathol; 2018 May; 46(5):369-377. PubMed ID: 29516685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid Ultrasound-Guided Fine-Needle Aspiration Cytology Results: Observed Increase in Indeterminate Rate over the Past Decade.
    Manning AM; Yang H; Falciglia M; Mark JR; Steward DL
    Otolaryngol Head Neck Surg; 2017 Apr; 156(4):611-615. PubMed ID: 28118554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules.
    Scola WH; Linhares SM; Handelsman RS; Picado O; Khan ZF; Farrá JC; Lew JI
    J Surg Res; 2021 Dec; 268():209-213. PubMed ID: 34358733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclassification of Bethesda Atypical and Follicular Neoplasm Categories According to Nuclear and Architectural Atypia Improves Discrimination of Thyroid Malignancy Risk.
    Lim JXY; Nga ME; Chan DKH; Tan WB; Parameswaran R; Ngiam KY
    Thyroid; 2018 Apr; 28(4):511-521. PubMed ID: 29596039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of repeat fine-needle aspiration in thyroid nodules categorized as atypia of undetermined significance or follicular lesion of undetermined significance: A single center experience.
    Marin F; Murillo R; Diego C; Jodar E; Acevedo A
    Diagn Cytopathol; 2021 Mar; 49(3):412-417. PubMed ID: 33252841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
    Hyeon J; Ahn S; Shin JH; Oh YL
    Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Malignancy Rates in Fine-Needle Aspiration Cytologies in a Primary Care Setting in Germany.
    Eszlinger M; Ullmann M; Ruschenburg I; Böhme K; Görke F; Franzius C; Adam S; Molwitz T; Landvogt C; Amro B; Hach A; Feldmann B; Graf D; Wefer A; Niemann R; Bullmann C; Klaushenke G; Santen R; Tönshoff G; Ivancevic V; Kögler A; Bell E; Lorenz B; Kluge G; Hartenstein C; Paschke R
    Thyroid; 2017 Nov; 27(11):1385-1392. PubMed ID: 28982301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material.
    Kartal K; Onder S; Kosemehmetoglu K; Kilickap S; Tezel YG; Kaynaroglu V
    BMC Cancer; 2015 Oct; 15():824. PubMed ID: 26519197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Stratification of Thyroid Nodules With Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS) Cytology Using Ultrasonography Patterns Defined by the 2015 ATA Guidelines.
    Lee JH; Han K; Kim EK; Moon HJ; Yoon JH; Park VY; Kwak JY
    Ann Otol Rhinol Laryngol; 2017 Sep; 126(9):625-633. PubMed ID: 28719972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bethesda Category III, IV, and V Thyroid Nodules: Can Nodule Size Help Predict Malignancy?
    Kiernan CM; Solórzano CC
    J Am Coll Surg; 2017 Jul; 225(1):77-82. PubMed ID: 28223197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.